Cargando…

PRIMA-1(met) (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms

PRIMA-1(met) (APR-246) is a methylated derivative and structural analog of PRIMA-1 (p53 re-activation and induction of massive apoptosis). PRIMA-1(met) has been reported to restore both the wild type (wt) structure and function of mutant p53. Here, we show that PRIMA-1(met) is highly effective at li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiao-Lan, Zhou, Jianbiao, Chan, Zit-Liang, Chooi, Jing-Yuan, Chen, Zhi-Rong, Chng, Wee-Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742204/ https://www.ncbi.nlm.nih.gov/pubmed/26452133

Ejemplares similares

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
por: Menichini, Paola, et al.
Publicado: (2021)

Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1(MET)/APR-246
por: Aberdam, Edith, et al.
Publicado: (2020)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, Xiaoxiao, et al.
Publicado: (2017)

PRIMA-1(met) induces autophagy in colorectal cancer cells through upregulation of the mTOR/AMPK-ULK1-Vps34 signaling cascade
por: Li, Xiao-Lan, et al.
Publicado: (2021)

PRIMA-1(Met) suppresses colorectal cancer independent of p53 by targeting MEK
por: Lu, Tao, et al.
Publicado: (2016)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Tumor-derived exosomes in colorectal cancer progression and their clinical applications
por: Zhou, Jianbiao, et al.
Publicado: (2017)

A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase
por: Zhou, Jianbiao, et al.
Publicado: (2018)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2019)

PRIMA-1(MET) Inhibits Growth of Mouse Tumors Carrying Mutant p53
por: Zache, Nicole, et al.
Publicado: (2008)

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia
por: Zhou, Jianbiao, et al.
Publicado: (2017)

Piperlongumine and p53-Reactivator APR-246 Selectively Induce Cell Death in HNSCC by Targeting GSTP1
por: Hang, Wei, et al.
Publicado: (2018)

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
por: Haffo, Lena, et al.
Publicado: (2018)

Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
por: Milne, Julia V., et al.
Publicado: (2021)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
por: Synnott, Naoise C., et al.
Publicado: (2018)

PRIMA-1(MET)-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
por: Mlakar, Vid, et al.
Publicado: (2019)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Sensitivity to PRIMA-1(MET) is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status
por: Patyka, Mariia, et al.
Publicado: (2016)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
por: Ceder, Sophia, et al.
Publicado: (2020)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
por: Fang, Y., et al.
Publicado: (2022)

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
por: Ghosh, Arnab, et al.
Publicado: (2022)

Targeting Oxidative Stress With Auranofin or Prima-1(Met) to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
por: Tessoulin, Benoit, et al.
Publicado: (2019)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2021)

APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
por: McCubrey, James Andrew, et al.
Publicado: (2022)

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
por: Zhou, Jianbiao, et al.
Publicado: (2018)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
por: Birsen, Rudy, et al.
Publicado: (2021)

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nq7aufjslta4542bo08sd0hfj7